The research company Curasight has carried out a directed new share issue that adds 16.4 million Danish kroner, corresponding to 24.2 million Swedish kronor, before issue costs. This is stated in a press release.The issue comprises approximately 2.06 million shares at a subscription price of 7.98 Danish kroner per share, which was determined through an accelerated bookbuilding process. The subscription price corresponds to a discount of around 20 percent versus Friday’s closing price.Subscribers in the issue were a number of Nordic and international institutional and professional investors, including new and existing ones.The dilution effect is approximately 4.29 percent of the capital in Curasight.In addition to the issue, the company has entered into a loan agreement with Fenja Capital II. Together with the issue, this financing will be used to support the clinical development of uTrace and uTreat, as well as strengthen the company’s financial position